| First Author | Chen H | Year | 2017 |
| Journal | Neurosci Lett | Volume | 657 |
| Pages | 126-133 | PubMed ID | 28757391 |
| Mgi Jnum | J:252242 | Mgi Id | MGI:5924978 |
| Doi | 10.1016/j.neulet.2017.07.048 | Citation | Chen H, et al. (2017) Systemic dexmedetomidine attenuates mechanical allodynia through extracellular sign db type 2 diabetic mice. Neurosci Lett 657:126-133 |
| abstractText | Painful diabetic neuropathy (PDN) is a common complication of diabetes mellitus. However, the treatment for PDN is limited in clinical practice. In the present study, we investigated the effect of systemic administration dexmedetomidine (DEX), a selective alpha 2 adrenergic receptor (alpha2AR) agonist, on mechanical allodynia and its underlying mechanism in db/db mice, an animal model of type 2 diabetes mellitus. Our data demonstrated that db/db mice develop mechanical allodynia at the early stage of diabetes. During the period of mechanical allodynia, we detected increased release of norepinephrine (NE) and decreased levels of alpha2A-Adrenoceptors in db/db mice. Immunohistochemistry showed that the alpha2A-Adrenoceptor is predominantly expressed in neurons in the spinal cord. Acute injection of dexmedetomidine significantly decreased mechanical allodynia, which was blocked by its selective antagonist BRL44408. Furthermore, the upregulation of pERK1 and pERK2 in db/db mice were attenuated by preadministration of dexmedetomidine. We provide the first evidence that the functional alternation of spinal noradrenergic system might underlie exaggerated nociception in PDN. Systemic dexmedetomidine inhibits the mechanical allodynia which is related to ERK signaling pathway in type 2 diabetes, implying that the alpha2-Adrenoceptor might be a potential therapeutic strategy for PDN. |
